XORTX Net Receivables from 2010 to 2024

XRTX Stock  USD 1.19  0.03  2.59%   
XORTX Therapeutics Net Receivables yearly trend continues to be fairly stable with very little volatility. Net Receivables will likely drop to about 35.1 K in 2024. During the period from 2010 to 2024, XORTX Therapeutics Net Receivables regression line of annual values had r-squared of  0.49 and arithmetic mean of  22,263. View All Fundamentals
 
Net Receivables  
First Reported
2014-12-31
Previous Quarter
22.8 K
Current Value
13.1 K
Quarterly Volatility
453.7 K
 
Yuan Drop
 
Covid
Check XORTX Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among XORTX Therapeutics' main balance sheet or income statement drivers, such as Selling General Administrative of 996.5 K, Other Operating Expenses of 2.6 M or Total Operating Expenses of 2.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.89. XORTX financial statements analysis is a perfect complement when working with XORTX Therapeutics Valuation or Volatility modules.
  
Check out the analysis of XORTX Therapeutics Correlation against competitors.
For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.

Latest XORTX Therapeutics' Net Receivables Growth Pattern

Below is the plot of the Net Receivables of XORTX Therapeutics over the last few years. It is XORTX Therapeutics' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in XORTX Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

XORTX Net Receivables Regression Statistics

Arithmetic Mean22,263
Geometric Mean12,270
Coefficient Of Variation105.36
Mean Deviation18,282
Median10,173
Standard Deviation23,456
Sample Variance550.2M
Range80.1K
R-Value0.70
Mean Square Error303.2M
R-Squared0.49
Significance0
Slope3,665
Total Sum of Squares7.7B

XORTX Net Receivables History

202435.1 K
202360.7 K
202281.8 K
202140.7 K
202014.4 K
201915.5 K
201830.3 K

About XORTX Therapeutics Financial Statements

XORTX Therapeutics investors use historical fundamental indicators, such as XORTX Therapeutics' Net Receivables, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in XORTX Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Receivables60.7 K35.1 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.